Background And Objectives: Over a third of adults in the United States have limited health literacy, which has been associated with numerous negative health outcomes and high health care costs. Most commonly used, objective measures of patients' literacy skills have traditionally been administered in person. This study assessed the feasibility of administering the Rapid Estimate of Adult Literacy in Medicine (REALM) via telephone.
Methods: A total of 119 participants were recruited after participating in a separate study where the REALM was administered in person. After approximately 1 week, patients were sent copies of the REALM prompt via mail and, when provided, email. A research assistant called participants approximately 1 week later to determine if the REALM had been received and could be accessed for use during the call. Multiple attempts to reach participants were made; 84 participants were able to successfully complete the study, yielding a response rate of 70.6%. The REALM was then administered over the phone, and results were compared with the scores from the in-person administration.
Results: There was a high correlation between both assessments (Spearman=0.85). The agreement between literacy categories (low, marginal, and adequate) between the in-person and telephone-based assessments was also high at 84.5% (kappa=0.72). Participants who completed the study were older than participants who did not complete the study, more likely to be white, and less likely to be currently working.
Conclusions: The findings from this study indicate the REALM can be administered over the phone, providing alternative methodologies for literacy assessments in future studies.
Download full-text PDF |
Source |
---|
Theranostics
January 2025
Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Local immunomodulation with nanoparticles (NPs) and focused ultrasound (FUS) is recognized for triggering anti-tumor immunity. However, the impact of these tumor immunomodulations on sex-specific microbiome diversity at distant sites and their correlation with therapeutic effectiveness remains unknown. Here, we conducted local intratumoral therapy using immunogenic cell death-enhancing Calreticulin-Nanoparticles (CRT-NPs) and FUS in male and female mice.
View Article and Find Full Text PDFSci Rep
December 2024
Faculty of Psychology, MOE Key Laboratory of Cognition and Personality, Southwest University, Chongqing, People's Republic of China.
Social exclusion has wide-ranging and detrimental effects. This study recruited 771 Chinese college students (Mage = 19.65 years, SDage = 1.
View Article and Find Full Text PDFFront Pharmacol
December 2024
Department of oncology, The Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, China.
Introduction: The Xihuang Pill (XHP), a venerated traditional Chinese medicine, has demonstrated significant anti-cancer capabilities. Despite its proven efficacy, the scarcity of comprehensive pharmacological studies limits the widespread application of XHP. This research endeavor seeks to demystify the therapeutic underpinnings of XHP, particularly in the realm of colorectal cancer (CRC) therapy.
View Article and Find Full Text PDFClin Ther
January 2025
Medical Dermatology Associates of Chicago, Chicago, Illinois.
Purpose: Lebrikizumab is a novel, high-affinity immunoglobulin G4 monoclonal antibody that targets interleukin-13, a central mediator in atopic dermatitis (AD). In previous studies in patients with moderate-to-severe AD, lebrikizumab, administered subcutaneously via a prefilled syringe with a needle safety device (PFS-NSD), demonstrated rapid and durable dose-dependent efficacy. We assessed the pharmacokinetics and safety of lebrikizumab using either a PFS-NSD or an investigational autoinjector.
View Article and Find Full Text PDFTurk J Emerg Med
October 2024
Department of Tanvi Snehal Desai, Emergency Medicine, Dr. D. Y. Patil Medical College and Hospital, Dr. D. Y. Patil Vidyapeeth, Pimpri, Maharashtra, India.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!